Ready To Use Dantrolene Compositions

Orbicular Pharmaceutical Technologies Private Limited
Withdrawn App No 202047039254 Chemical

Patent information

IP India · live record
Application number
202047039254
Filing date
11 September 2020
Status
Withdrawn
Publication number
40/2020
Publication type
INA
Invention field
Chemical

Abstract

The present invention relates to a stable, multidose, ready to use, non-aqueous compositions comprising (i) dantrolene or pharmaceutically acceptable salts thereof; (ii) non-aqueous solvent system suitable for injection; wherein dantrolene was substantially dissolved in the non-aqueous solvent system; wherein non-aqueous solvent system is free of polar aprotic solvents.

Applicants

1
India
ORBICULAR PHARMACEUTICAL TECHNOLOGIES PRIVATE LIMITED P. No. 53 Aleap Industrial Estate Pragati Nagar, Kukatpally Hyderabad-500 090, Telangana

Inventors

6
India
MOHAN, Mailatur SivaramanOrbicular Pharmaceutical Technologies Pvt. Ltd. P. No. 53 Aleap Industrial Estate Pragati Nagar, Kukatpally Hyderabad-500 090, Telangana
India
PATEL, HirenOrbicular Pharmaceutical Technologies Pvt. Ltd. P. No. 53 Aleap Industrial Estate Pragati Nagar, Kukatpally Hyderabad-500 090, Telangana
India
VALLABHBHAI PATEL, BhaveshkumarOrbicular Pharmaceutical Technologies Pvt. Ltd. P. No. 53 Aleap Industrial Estate Pragati Nagar, Kukatpally Hyderabad-500 090, Telangana
India
KANNEKANTI, RaghuOrbicular Pharmaceutical Technologies Pvt. Ltd. P. No. 53 Aleap Industrial Estate Pragati Nagar, Kukatpally Hyderabad-500 090, Telangana
India
KANTU, BabujiOrbicular Pharmaceutical Technologies Pvt. Ltd. P. No. 53 Aleap Industrial Estate Pragati Nagar, Kukatpally Hyderabad-500 090, Telangana
India
PATEL, RagneshkumarOrbicular Pharmaceutical Technologies Pvt. Ltd. P. No. 53 Aleap Industrial Estate Pragati Nagar, Kukatpally Hyderabad-500 090, Telangana

Specification

Show full textCollapse

We Claim, 1. A stable, multidose, ready to use, non-aqueous composition comprising (i) dantrolene or pharmaceutically acceptable salts thereof (ii) non-aqueous solvent system suitable for injection; wherein dantrolene was substantially dissolved in the non-aqueous solvent system; wherein non-aqueous solvent system is free of polar aprotic solvents. 2. The composition of claim 1, where in composition comprising from about 25 mg/mL to about 175 mg/mL of dantrolene or pharmaceutically acceptable salts thereof. 3. The composition of claim 1 wherein, composition comprising non-aqueous solvents selected from the group comprising of glycerol, propylene glycol, ethanol, polyethylene glycol, methanol, 1-butanol, 2-butanol, tertiary butanol, isopropanol, 1-propanol, or mixtures thereof. 4. The composition of claim 3, where in non-aqueous solvent system preferably comprising propylene glycol, polyethylene glycol, ethanol and combinations thereof. 5. The composition of claim 1, wherein the composition further comprises at least one pharmaceutically acceptable excipients selected form the group of solubilizers, stabilizers, buffering agents, tonicity contributing agents, pH adjusting agents. 6. The composition of claim 1, wherein the composition is having a pH ranging from about 5.0 to about 11. 7. The composition of claim 5, wherein the stabilizers include surfactants, antioxidants, chelating agents, proteins, polymers and combinations thereof. 8. The composition of claim 1, upon reconstituted with sterile water for injection forms a colloidal suspension, wherein the mean particle size of dantrolene was less than 1 micron. 9. The composition of claim 1, used for the treatment of malignant hyperthermia, heat stroke and other related disorders.

Documents

Sign in to open
Application documents
1 202047039254-FORM 1 [11-09-2020(online)].pdf 11 Sep 2020
2 202047039254-COMPLETE SPECIFICATION [11-09-2020(online)].pdf 11 Sep 2020
3 202047039254.pdf 18 Oct 2021